# Guardant Health Receives FDA Approval for Guardant360 Liquid CDx Advanced Liquid Biopsy Panel

> fda · REPORTED · 2026-06-30

Guardant Health received FDA approval for Guardant360 Liquid CDx as the most advanced FDA-approved liquid biopsy panel, and also received a separate FDA approval for the panel as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS in HER2-mutant advanced non-small cell lung cancer.

About Guardant Health: Guardant Health is a precision oncology company that develops liquid biopsy blood tests and genomic analysis platforms used for cancer detection, treatment selection, and monitoring in patients with solid tumors.

- Company: Guardant Health
- Sector: diagnostics
- Primary source: https://www.sec.gov/Archives/edgar/data/0001576280/000157628026000036/gh-06302026xexhibit991.htm

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.